MiNK Therapeutics, Inc.
INKT
$14.72
-$0.44-2.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -0.74% | -63.06% | -35.25% | -40.51% | -22.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.87% | -20.60% | -63.92% | -54.26% | -34.58% |
| Operating Income | 33.87% | 20.60% | 63.92% | 54.26% | 34.58% |
| Income Before Tax | 27.45% | 54.88% | 64.69% | 56.40% | 32.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 27.45% | 54.88% | 64.69% | 56.40% | 32.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.45% | 54.88% | 64.69% | 56.40% | 32.94% |
| EBIT | 33.87% | 20.60% | 63.92% | 54.26% | 34.58% |
| EBITDA | 34.27% | 21.79% | 64.76% | 54.60% | 34.99% |
| EPS Basic | 36.60% | 60.59% | 69.19% | 59.61% | 34.25% |
| Normalized Basic EPS | 40.47% | 34.35% | 69.19% | 56.84% | 34.24% |
| EPS Diluted | 36.60% | 21.07% | 69.19% | 59.61% | 35.25% |
| Normalized Diluted EPS | 40.47% | 34.35% | 69.19% | 56.84% | 34.24% |
| Average Basic Shares Outstanding | 14.45% | 14.50% | 14.60% | 7.94% | 1.99% |
| Average Diluted Shares Outstanding | 14.45% | 14.50% | 14.60% | 7.94% | 1.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |